SLC5A2 and diabetes mellitus: In addition, several recent studies have suggested that SGLT2 inhibitors have a cardioprotective effect, such as the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose) trial and DECLARE TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58) trial (Zinman et al., 2015; Wiviott et al., 2019).